J Cancer Prev 2022; 27(1): 1-6
Published online March 30, 2022
© Korean Society of Cancer Prevention
1Division of Genetics, Cancer Research Institute, Kanazawa University, 2WPI Nano-Life Science Institute (Nano-LSI), Kanazawa University, Kanazawa, Japan, 3Cancer Immunology and Immunotherapy Unit, Cancer Research Malaysia, Selangor, Malaysia
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comprehensive genome analyses have identified frequently mutated genes in human colorectal cancers (CRC). These include APC, KRAS, SMAD4, TP53, and FBXW7. The biological functions of the respective gene products in cell proliferation and homeostasis have been intensively examined by in vitro experiments. However, how each gene mutation or combinations of specific mutations drive malignant progression of CRC in vivo has not been fully understood. Based on the genomic information, we generated mouse models that carry multiple mutations of CRC driver genes in various combinations, and we performed comprehensive histological analyses to link genetic alteration(s) and tumor phenotypes, including liver metastasis. In this review article, we summarize the phenotypes of the respective genetic models carrying major driver mutations and discuss a possible mechanism of mutations underlying malignant progression.
Keywords: Transgenic mice, Organoid, Colorectal cancer, Mutations, Elastic modulus
Soojung Jin, Jung-ha Park, Hee Jung Yun, You Na Oh, Seunghye Oh, Yung Hyun Choi, Byung Woo Kim, Hyun Ju KwonJ Cancer Prev 2022; 27(4): 221-228 https://doi.org/10.15430/JCP.2022.27.4.221
Qinglong Liu, Xiaojing Li, Hao Zhang, Haitao LiJ Cancer Prev 2022; 27(1): 31-41 https://doi.org/10.15430/JCP.2022.27.1.31
Yi-Wen Huang,*, Chien-Wei Lin,*, Pan Pan,*, Carla Elena Echeveste, Athena Dong, Kiyoko Oshima, Martha Yearsley, Jianhua Yu,**, Li-Shu Wang,**J Cancer Prev 2021; 26(1): 32-40 https://doi.org/10.15430/JCP.2021.26.1.32